{
  "id": 10453509,
  "title": "STAT+: AbbVie wins FDA nod for Parkinson’s pill",
  "url": "https://urgent.news/2026/09/28/stat-abbvie-wins-fda-nod-for-parkinsons-pill",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-28T13:40:32.000Z",
  "source": {
    "name": "STAT News",
    "slug": "stat-news",
    "url": "https://www.statnews.com/2026/09/28/biotech-news-abbvie-wins-fda-nod-for-parkinsons-pill/"
  },
  "original_language": "en",
  "account": "AbbVie secures FDA approval for its Parkinson's medication, marking a significant milestone in treating this neurodegenerative disorder. Meanwhile, Zenkuda, a groundbreaking vision-sparing treatment for age-related blindness, demonstrates statistical equivalence to Eylea, a widely-used standard therapy, in a pivotal Phase 3 clinical trial. Merck has acquired global license rights to a preclinical cancer drug targeting tumors with KRAS G12D mutations, with an initial investment of $400 million from China’s SciBrunch Therapeutics, with a potential value of $2.13 billion if all future milestones are met. Novo Nordisk is increasingly positioning its GLP-1 drugs not just as treatments for chronic diseases, but as consumer products for weight loss, as insurance coverage for these obesity medications remains limited.",
  "summary": "The FDA has approved AbbVie’s once-daily Parkinson’s pill for sales, based on a late-stage study that showed the drug helped improve symptoms.",
  "key_points": [
    "AbbVie receives FDA approval for Parkinson's medication",
    "Zenkuda shows statistical equivalence to Eylea in trial",
    "Merck acquires global rights to KRAS G12D cancer drug"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}